Maravai LifeSciences Holdings Inc Ordinary Shares - Class A MRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
-
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
-
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
-
Maravai LifeSciences Reports First Quarter 2026 Financial Results
-
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 147.51M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 570.66
- Price/Sales
- 4.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 416
- Website
- https://www.maravai.com
Valuation
|
Metric
|
MRVI
|
|---|---|
Price/Earnings (Normalized) | 570.66 |
Price/Book Value | 4.43 |
Price/Sales | 4.51 |
Price/Cash Flow | — |
Price/Earnings
MRVI
Financial Strength
|
Metric
|
MRVI
|
|---|---|
Quick Ratio | 4.68 |
Current Ratio | 5.91 |
Interest Coverage | −6.66 |
Quick Ratio
MRVI
Profitability
|
Metric
|
MRVI
|
|---|---|
Return on Assets (Normalized) | −5.96% |
Return on Equity (Normalized) | −20.20% |
Return on Invested Capital (Normalized) | −4.40% |
Return on Assets
MRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x!VslQG | LOCK|^@fl | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R#^!mfz | LOCK|%nJgV | $70B | |||
| argenx SE ADR
ARGX
| LOCK|LFpDdPf | LOCK|dp^ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|jL#st^ | LOCK|n#gb | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l#J!X? | LOCK|M@ | $36B | |||
| Moderna Inc
MRNA
| LOCK|@?gd$^< | LOCK|z% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&pFMT<w | LOCK|?mj^j | $25B | |||
| Incyte Corp
INCY
| LOCK|^BC&wk | LOCK|BK | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qxN##bW | LOCK|&Y | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|knW@<!B | LOCK|Pl | $16B |
United States